Despite the reduced number of working days due to the Lunar New Year holiday, over 14 biotechnology companies reported year-over-year revenue growth exceeding 10% in January. Among them, MYCENAX BIOTECH and PharmaEssentia saw their revenue more than double. Additionally, SYN-TECH and SCI Pharmtech, having recovered from past fire incidents, posted double-digit revenue growth following the restoration of their production capacities, drawing significant attention to their full-year growth potential.
Meanwhile, DeepSeek’s advancements have fueled the broader adoption of AI applications, positioning medical AI as a key industry focus. EVER FORTUNE AI, in addition to planning a cash dividend distribution of NT$1 per share, has secured 43 medical device approvals domestically and internationally, including 12 FDA certifications in the U.S. This year, the company will continue to expand its multi-faceted integration of products across three major areas: neurology, cardiovascular health, and oncology. It is also actively pursuing certification and listing on major online platforms in Europe and the U.S. to enhance its international presence.
PharmaEssentia has continued its strong momentum since the beginning of the Lunar New Year, reporting a January revenue of NT$1.06 billion, marking a 107.87% year-over-year increase and exceeding NT$1 billion in revenue for three consecutive months. Analysts anticipate that the company's annual revenue will surpass NT$10 billion this year, with significant profit growth.
CEO Ko-Chung Lin highlighted that PharmaEssentia’s blood cancer drug, Ropeg, has received regulatory approval in approximately 40 countries. Due to a supply shortage of Pegasys, a competing product, multiple countries are facing gaps in supply. In response, the Canadian government has granted Ropeg expedited approval, and its sales in Europe surged fivefold last year. Given these trends, the company remains highly optimistic about its 2024 business outlook.
Following the successful regulatory inspections and resumption of production at its newly reconstructed facilities, SYN-TECH set a record-high annual revenue of NT$1.258 billion in 2024. Its January revenue reached NT$96 million, reflecting an 18.13% year-over-year increase. With its newly expanded production capacity nearly fully utilized, the company plans to invest NT$128 million to acquire a 1,130-ping (approximately 3,700-square-meter) plot adjacent to its factory for further expansion, ensuring sustained growth in the coming years.
SCI Pharmtech, having fully restored its production capacity after last year’s fire disruption, has maintained a steady monthly revenue of NT$130 million to NT$160 million since Q3. In January, the company reported NT$107 million in revenue, up 15.03% year-over-year.
Although SCI Pharmtech's newly added production capacity has yet to reach full utilization, its profitability has been affected by increased depreciation and amortization costs as well as a decline in antidepressant drug prices. However, its glaucoma drug ingredients have successfully entered the supply chain of an original manufacturer, and the progress of its Alzheimer’s drug launch, along with new customer acquisitions, is expected to drive growth in 2024.
Resource: 永昕、藥華藥 元月營收年增翻倍
